Marc I. Diamond, MD

Specialty Areas
Muscular Dystrophy
Huntington's Disease
Movement Disorders
Neurology - Adult

Areas of Clinical Interest
Neurodegenerative disease, polyglutamine disease, spinobulbar muscular atrophy, Huntington disease, prostate cancer, nuclear receptor function, regulation of protein folding, chemical/genetic screening, cell and molecular biology, neuroscience.


Honors and Awards
Leadership Award, Huntington's Disease Society of America, 2007
Sandler Opportunity Award, 2007
Global Life Science Innovation Competition at UCSF Merck Research Laboratories prize for Innovation, First Prize; prize for Clinical Impact (runner-up); Overall competition (finalist).
Sandler Award for Innovation in Basic Science, 2002, 2005

Publications

Li, M; Huang, Y; Ma, AK; Lin, E; and Marc I. Diamond: “Y-27632 improves rotarod performance and reduces huntingtin levels in R6/2 mice” Neurobiology of Disease 2009 (in press)

Frost, B and Marc I. Diamond: “The expanding realm of prion phenomena in neurodegenerative disease.” Prion 2009 3(2) (Epub)

Frost, B; Jacks, RL; and Marc I. Diamond: "Propagation of tau misfolding from the outside to the inside of a cell." Journal of Biological Chemistry 2009 284(19):12845-52 Cited in Nature: News and Views 2009 459: 924-925

Jones, JO; An, WF, and Marc I. Diamond: “AR Inhibitors identified by high throughput microscopy detection of conformational change and subcellular localization.” ACS/Chemical Biology 2009 4(3):191-7

Jones, JO; Bolton, EC; Huang, Y; Clementine, F; Guy, RK; Yamamoto, KR; Hann, B and Marc I. Diamond: “Ligand independent androgen receptor inhibition in vitro and in vivo.” Proceedings of the National Academy of Sciences 2009 106(17):7233-8 Cited in Nature Reviews/Cancer: 2009 9(6):386-7, and Nature Reviews/Drug Discovery 2009 8(6):452

Gerber, AN; Misuno, K; and Marc I. Diamond: "Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening.” Proceedings of the National Academy of Sciences 2009 106(12):4929-34

Frost, B; Ollesch, J; Wille H and Marc I. Diamond: “Conformational diversity of wild-type tau fibrils specified by templated conformational change.” Journal of Biological Chemistry 2009 284(6):3546-51.

Chandra, S; Shao, J; Li, JX; Li, M; Longo, FM, and Marc I. Diamond: “A common motif targets huntingtin and the androgen receptor to the proteasome.” Journal of Biological Chemistry 2008 283(35):23950-5

Shao, J; Welch, WJ and Marc I. Diamond: “Phosphorylation of profilin by p160ROCK reduces polyglutamine aggregation” Molecular and Cellular Biology 2008 28(17):5196-208

Jones, JO and Marc I. Diamond: " A cellular conformation-based screen for androgen receptor inhibitors" ACS/Chemical Biology 2008 3(7):412-418

Ryan CJ, Zavodovskaya M, Youngren JF, Campbell M, Diamond MI, Jones J, Shiry L, Allan G, Maddux BA, Goldfine ID: Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells. Prostate 2008 68(11):1232-40

Shao, J; Welch, WJ and Marc I. Diamond: “ROCK and PRK-2 mediate the inhibitory effect of Y-27632 on polyglutamine aggregation.” FEBS Letters 2008 582(12):1637-42.

Jones, JO and Marc I. Diamond: “Design and utilization of cell-based assays to model human disease.” ACS/Chemical Biology 2007 2(11):718-24.

Shao, J and Marc I. Diamond: “Polyglutamine diseases: emerging concepts and therapeutic opportunities.” Human Molecular Genetics 2007 R16(2):R116-123.

Cvoro A, Paruthiyil S, Jones JO, Tzagarakis-Foster C, Clegg NJ, Tatomer D, Medina RT, Tagliaferri M, Schaufele F, Scanlan TS, Diamond MI, Cohen I, Leitman DC: “Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract.” Endocrinology 2007 Feb;148(2):538-47.

Li M, Chevalier-Larsen ES, Merry DE, and Marc I. Diamond: “Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy.” Journal of Biological Chemistry 2007 Feb 2;282(5):3157-64.

Desai UA, Pallos J, Ma AA, Stockwell BR, Thompson LM, Marsh JL and Marc I. Diamond: Biologically active molecules that reduce polyglutamine aggregation and toxicity. Human Molecular Genetics 2006 Jul 1;15(13):2114-24

Schaufele, F; Carbonell, X; Guerbadot, M; Borngraeber, S; Ma, AK; Chapman, MS; Miner, JN; and Marc I. Diamond: “The Structural basis of AR activation: intramolecular and intermolecular amino-carboxy interactions” Proceedings of the National Academy of Sciences, 2005; 102(28):9802-7

Pollitt, SK, Pallos, J, Shao, J, Desai, UA, Ma, AK, Thompson, LM, Marsh, JL, and Marc I. Diamond: “A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor” Neuron, 2003; 40:685-94

Cowan, KJ, Diamond, MI, and William J. Welch: “Polyglutamine protein aggregation and toxicity are linked to the cellular stress response” Human Molecular Genetics, 2003; 12(12):1377-91.

Welch, WJ and Marc I. Diamond: “Glucocorticoid modulation of androgen receptor nuclear aggregation and cellular toxicity is associated with distinct forms of soluble expanded polyglutamine protein” Human Molecular Genetics, 2001; 10(26):3063-3074

Diamond, MI; Robinson, MR and Keith R Yamamoto “Glucocorticoid regulation of polyglutamine protein aggregation and nuclear localization” Proceedings of the National Academy of Sciences, 2000; 97(2):657-61.

Neurology / Adult

---

Neurology

---

Neuroscience Center

---

Health Insurance Plans Accepted

Back to Physician's Directory